Liminatus Pharma is set to advance IBA101, a next-generation CD47 inhibitor designed to avoid the severe side effects that halted previous therapies, into human trials in the U.S. and Korea by early 2027. This innovative drug promises to redefine cancer immunotherapy by targeting tumors while sparing healthy cells, potentially offering new hope to patients.